IP Verse

Light Inhibitors For Asthma, Lung And Airway Inflammation, Respiratory, Interstitial, Pulmonary And Fibrotic Disease Treatment - EP2207597

The patent EP2207597 was granted to Lajolla Institute FOR Allergy And Immunology on Feb 19, 2020. The application was originally filed on Sep 18, 2008 under application number EP08831796A. The patent is currently recorded with a legal status of "Revoked".

EP2207597

LAJOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
Application Number
EP08831796A
Filing Date
Sep 18, 2008
Status
Revoked
Jun 2, 2023
Grant Date
Feb 19, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

EUROPEAN OPPOSITIONSNov 19, 2020LEONARD -

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONWO2008027338
INTERNATIONAL-SEARCH-REPORTEP1336619
INTERNATIONAL-SEARCH-REPORTWO2004024076
INTERNATIONAL-SEARCH-REPORTWO2006054961
OPPOSITIONEP1336619
OPPOSITIONWO0142463
OPPOSITIONWO0179496
OPPOSITIONWO2008027338

Non-Patent Literature (NPL) Citations (17) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- G. CONN, D. D. SODERMAN, M. T. SCHAEFFER, M. WILE, V. B. HATCHER, K. A. THOMAS, "Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line.", PNAS, (1990), vol. 87, no. 4, pages 1323 - 1327-
EXAMINATION- R&D Systems - Safety data sheet: Human LIGHT/TNFSF14 antibody; Catalog Number: AF664-
INTERNATIONAL-SEARCH-REPORT- KWON B ET AL, "INVOLVEMENT OF TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) MEMBERS IN THE PATHOGENESIS OF INFLAMMATORY DISEASES", EXPERIMENTAL AND MOLECULAR MEDICINE, SEOUL, KR, (20030228), vol. 35, no. 1, ISSN 1226-3613, pages 8 - 16, XP009014004 [A] 1-30,32-48 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- DOHERTY T A ET AL, "The TNF family member LIGHT is critical for Th2-driven murine lung inflammation and airway remodeling", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, & 64TH ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-ALLERGY-ASTHMA-AND-IMM UNOLOGY; PHILADELPHIA, PA, USA; MARCH 14 -18, 2008, (200802), vol. 121, no. 2, Suppl. 1, ISSN 0091-6749, page S114, XP002532006 [PX] 1-17,19-28,30,32-45 * the whole document *
INTERNATIONAL-SEARCH-REPORT- WARE C F, "Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways", IMMUNOLOGICAL REVIEWS 200806 GB, (200806), vol. 223, no. 1, ISSN 0105-2896 1600-065X, pages 186 - 201, XP002532007 [PA] 1-30,32-48 * the whole document *
OPPOSITION- Anonymous, "Acute Lung Injury", Nunn's Applied Respiratory Physiology, (20170000), page 439e1, XP055757291-
OPPOSITION- Anonymous, "Sclerosis", Concise Medical Dictionary, (20100000), page 1, XP055757315-
OPPOSITION- Anonymous, "What is Pulmonary Fibrosis", www.blf.org.uk, (20201023), pages 1 - 2, URL: https://www.blf.org.uk/support-for-you/pulmonary-fibrosis/what-is-pulmonary-fibrosis accessed, XP055757273-
OPPOSITION- BETTENWORTH D et al., "Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review", Gut, (20190000), vol. 68, no. 6, pages 1115 - 1126, XP055757327-
OPPOSITION- JUNG et al., "High levels of soluble herpes virus entry mediator in sera of patients with allergic and autoimmune diseases", Exp Mol Med, (20030000), vol. 35, pages 501 - 508, XP003026542-
OPPOSITION- REDINGTON AE, "Airway fibrosis in asthma: mechanisms, consequences, and potential for therapeutic intervention", Monaldi Arch Chest Dis, (20000800), vol. 55, no. 4, pages 317 - 323, XP055757297-
OPPOSITION- ROSENBLOOM et al., "Human Fibrotic Diseases: Current Challenges in Fibrosis Research", Fibrosis: Methods and Protocols, Methods in Molecular Biology, (20170000), vol. 1627, pages 1 - 23, XP055757264-
OPPOSITION- KITKO et al., "Fibrotic and sclerotic manifestations of chronic graft-versus-host disease", Biol Blood Marrow Transplant, (20120000), vol. 18, doi:10.1016/j.bbmt.2011.10.021, pages S46 - S52, XP028434694
OPPOSITION- Doherty; Salek-Ardakani T A; Ware S; Scheu C F; Pfeffer S; Broide K; Croft D; M, "The TNF Family Member LIGHT is Critical for Th2-Driven Murine Lung Inflammation and Airway Remodeling", Journal of Allergy and Clinical Immunology, (20080200), vol. 121, no. 2, page S114, XP022548555
OPPOSITION- MAO-MAO AN et al., "Lymphtoxin beta receptor-Ig ameliorates TNBS-induced colitis via blocking LIGHT/HVEM signaling", Pharmacological Research, (20050000), vol. 52, no. 3, pages 234 - 244, XP004979394
OPPOSITION- RIEDER F et al., "Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science", Curr Opin Gastroenterol, (20080700), vol. 24, no. 4, doi:10.1097/MOG.0b013e3282ff8b36, pages 462 - 8, XP008175739
OPPOSITION- WANG et al., "The regulation of T cell homeostasis and autoimmunity by T cell -derived LIGHT", J. Clin. Invest., (20010000), vol. 108, doi:10.1172/JCI200113827, pages 1771 - 1780, XP002247515

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents